Selecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 Treatment

marketwatch2023-11-01

By Sabela Ojea

Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine to development and commercialization partner, Swedish Orphan Biovitrum.

The clinical stage biotechnology company on Tuesday said that Swedish Orphan Biovitrum will be responsible for the manufacturing and commercial supply of its Immtor immune tolerance platform for Sel-212.

Sel-212, a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme, aimed at treating chronic refractory gout.

The company didn't disclose financial terms of the agreement.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2380557579?lang=en_US&edition=fundamental","thumbnail":"https://images.barrons.com/im-29198610?size=1.777777777777778&width=220 220w","is_english":true,"pubTime":"2023-11-01 04:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2380557579","market":"us","top_or_hot":-1,"title":"Selecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 Treatment","media":"marketwatch","content":"<html><body><div itemprop=\"articleBody\" role=\"document\"> <div> <div> <div aria-hidden=\"true\"></div> </div> </div> <p>By Sabela Ojea</p><pre></pre> <p>Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine to development and commercialization partner, Swedish Orphan Biovitrum.</p> <p>The clinical stage biotechnology company on Tuesday said that Swedish Orphan Biovitrum will be responsible for the manufacturing and commercial supply of its Immtor immune tolerance platform for Sel-212.</p> <div> <p>Sel-212, a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme, aimed at treating chronic refractory gout.</p> <p>The company didn't disclose financial terms of the agreement.</p><pre></pre> <p>Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix</p><pre></pre> </div> </div></body></html>","source":"mwatch_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Selecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSelecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-01 04:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/selecta-biosciences-in-deal-to-transfer-manufacturing-development-rights-of-sel-212-treatment-94fb05b6?mod=newsviewer_click><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sabela Ojea Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine to development and commercialization ...</p>\n\n<a href=\"https://www.marketwatch.com/story/selecta-biosciences-in-deal-to-transfer-manufacturing-development-rights-of-sel-212-treatment-94fb05b6?mod=newsviewer_click\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.marketwatch.com/story/selecta-biosciences-in-deal-to-transfer-manufacturing-development-rights-of-sel-212-treatment-94fb05b6?mod=newsviewer_click","article_id":"2380557579","we_media_id":null,"thumbnails":["https://images.barrons.com/im-29198610?size=1.777777777777778&width=220 220w"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2380557579","pubTimestamp":1698783960,"columns":[],"sourceInfo":{"source_id":"mwatch_stock","name":"Market Watch"},"weMediaInfo":null,"summary":"By Sabela Ojea Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine to development and commercialization partner, Swedish Orphan Biovitrum. The clinical stage biotechnology company on Tuesday said that Swedish Orphan Biovitrum will be responsible for the manufacturing and commercial supply of its Immtor immune tolerance platform for Sel-212.  Sel-212, a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme, aimed at treating chronic refractory gout. The company didn't disclose financial terms of the agreement. Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"Selecta Biosciences在交易中转让Sel-212处理的生产和开发权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SELB":1},"content_text":"By Sabela Ojea Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine to development and commercialization partner, Swedish Orphan Biovitrum. The clinical stage biotechnology company on Tuesday said that Swedish Orphan Biovitrum will be responsible for the manufacturing and commercial supply of its Immtor immune tolerance platform for Sel-212.  Sel-212, a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme, aimed at treating chronic refractory gout. The company didn't disclose financial terms of the agreement. Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2380557579","isCrawlerRequest":true}